FCPM III SERVICES B.V. — 13F Holdings & Portfolio
CIK 2013410 · latest 13F-HR filed 2026-05-15
FCPM III SERVICES B.V. manages $722.2M in 13F-reported U.S. long-equity assets across 14 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are NAMS (20.60%), NAMS (20.17%), VOR (10.17%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 1 new position, exited 1, added to 3, and trimmed 6.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$722.2M
Long-equity book
14
Distinct positions
2026-03-31
Filed 2026-05-15
+1 / −1 / ↑3 / ↓6
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- VOR BIOPHARMA INC$26.1M +55.2%
- CRESCENT BIOPHARMA INC.$10.9M +54.9%
- MAPLIGHT THERAPEUTICS INC$8.9M +15.7%
Top Trims
- NEWAMSTERDAM PHARMA COMPANY-$28.2M -8.8%
- DYNE THERAPEUTICS INC-$22.7M -21.2%
- ENGENE HOLDINGS INC-$21.4M -24.6%
- BICYCLE THERAPEUTICS PLC-$8.5M -34.5%
- REPLIMUNE GROUP INC-$5.8M -21.3%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | NEWAMSTERDAM PHARMA COMPANY | NAMS | N62509109 | $148.8M | 20.60% | 4,648,025 | SH |
| 2 | NEWAMSTERDAM PHARMA COMPANY | NAMS | N62509109 | $145.7M | 20.17% | 4,550,875 | SH |
| 3 | VOR BIOPHARMA INC | VOR | 929033207 | $73.5M | 10.17% | 4,117,354 | SH |
| 4 | MAPLIGHT THERAPEUTICS INC | MPLT | 56565P103 | $65.6M | 9.08% | 3,226,400 | SH |
| 5 | DAMORA THERAPEUTICS INC | DMRA | 36322Q206 | $63.2M | 8.75% | 2,441,000 | SH |
| 6 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $58.3M | 8.08% | 3,218,016 | SH |
| 7 | ENGENE HOLDINGS INC | ENGNW | 29286M105 | $45.9M | 6.35% | 6,738,362 | SH |
| 8 | CRESCENT BIOPHARMA INC. | CBIO | G2545C104 | $30.8M | 4.27% | 1,677,852 | SH |
| 9 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $25.9M | 3.58% | 1,426,370 | SH |
| 10 | REPLIMUNE GROUP INC | REPL | 76029N106 | $21.5M | 2.97% | 2,808,368 | SH |
| 11 | ENGENE HOLDINGS INC | ENGNW | 29286M105 | $19.7M | 2.73% | 2,894,199 | SH |
| 12 | BICYCLE THERAPEUTICS PLC | BCYC | 088786108 | $16.1M | 2.23% | 3,468,430 | SH |
| 13 | ENGENE HOLDINGS INC | ENGNW | 29286M113 | $6.1M | 0.84% | 2,403,072 | SH |
| 14 | ENGENE HOLDINGS INC | ENGNW | 29286M113 | $1.2M | 0.17% | 475,076 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $722.2M | 14 | 0001193125-26-225423 |
| 2025-12-31 | 2026-02-17 | $762.9M | 14 | 0001193125-26-053151 |
| 2025-09-30 | 2025-11-14 | $500.4M | 13 | 0001193125-25-281853 |